X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

COVID-19 Vaccine – Has UK created the pressure to rush on other countries?

Content Team by Content Team
9th December 2020
in Drug Development, News
Abzena Invests $60M Into cGMP Manufacturing Capacity

Has UK’s announcement created the pressure on other countries to rush for a COVID-19 vaccine? Are we heading towards another who sends the man to the moon first scenario or is this thinking of ours far-fetched? The British Government’s announcement last week with regards to approval for Pfizer-BioNtech Covid vaccine for public use has not only brought in a lot of excitement and positive energy around the world but has raised eyebrows as well. Is it going to be a rush now of several other countries too jumping on the bandwagon and allowing the sale of vaccines? Well, that’s something we need to wait and watch as the time passes by. Hopefully, decisions are not taken in haste and the end product that comes out stands completely in line with all the requirements of how a COVID-19 vaccine should fare when administered across scores of people.

The world is seeing this as a monumental approval, but the announcement has turned heads around as well. US’s National Institute of Allergy and Infectious Diseases-NIAID Director, Anthony S. Fauci. M.D. has recently been quoted as saying that if one goes quickly and does the task superficially, people would not want to get vaccinated. According to him, the UK’s regulatory authority did not do this carefully. Although he did apologize a day after, saying that he has great faith in the UK regulators.

The scientist fraternity has already warned against this rush for a COVID-19 vaccine terming the outcome to be unrealistic and crazy. In normal times, a vaccine takes 10 years to develop. Just imagine something that comes up within 12 months. A small issue may put the entire vaccine program in jeopardy. The fact is that when a vaccine development moves from science to politics, it does draw attention. That said, we see a hope of a possible successful outcome of COVID vaccine in the public domain due to the conviction with which the Scientists, UK Government and Regulator have come out in the open to administer it in full throttle and organized way.

The focus on the rapid development of the vaccine seems to be fuelled by political, financial and social pressures. The idea is however not to jump the gun but come out with a dosage which is safe and can be used by all. The rush to allow public usage of COVID-19 vaccines was apparent when just hours after UK’s announcement, Russia too joined the club by going all out on the public distribution of Sputnik V. People may argue that all this has led to constructing a narrative that anything is better than nothing. It is also to be noted that the distribution of the vaccines is also going to be one torrid task which the regulators and authorities need to think about before making any such announcements.

We all are looking forward to having our lives back on track. But a substandard process surrounding the development of the vaccine or the consequences thereafter might as well harm us even more. What the UK has done by making this announcement is to build a path for others to follow. We only hope there is no place for a haphazard approach just to let others down because ultimately we are talking about human lives here. 

Previous Post

The UK begins the biggest ever immunization program

Next Post

U.S. FDA confirms Pfizer COVID vaccine safe & effective

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
Robots and AI in Drug
Articles

Robots and AI in Drug Discovery Are Transforming Medicine

29th May 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
Next Post
U.S. FDA confirms Pfizer COVID vaccine safe & effective

U.S. FDA confirms Pfizer COVID vaccine safe & effective

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In